A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2024-09-06
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2, open-label, multicentric, non-randomised, parallel-arm study that aims
to establish the safety, tolerability, and initial efficacy of CAN04 in combination with 3
SoC chemotherapies (mFOLFOX, DTX, and G/C).